Related Experiment Video
Updated: Feb 2, 2026

How to Obtain Reliable Visual Event-related Potentials in Newborns
Published on: October 24, 2019
Newborn screening in mucopolysaccharidoses
Maria Alice Donati1, Elisabetta Pasquini1, Marco Spada2
1Metabolic and Muscular Unit, Regional Reference Centre Expanded Newborn Screening, Meyer Children Hospital, Florence, Italy.
Insights
Newborn screening for mucopolysaccharidosis type I (MPS I) shows promise due to improved therapies. However, high rates of pseudodeficiency alleles, particularly in certain populations, complicate screening interpretation.
Area of Science:
- Biochemistry and Genetics
- Newborn Screening
- Metabolic Disorders
Background:
- Therapeutic options and newborn screening (NBS) methods for mucopolysaccharidoses (MPS) are advancing.
- Early intervention in MPS significantly improves patient outcomes.
- Mucopolysaccharidosis type I (MPS I) is being considered for inclusion in NBS panels globally.
Purpose of the Study:
- To evaluate the feasibility and challenges of implementing MPS I newborn screening.
- To assess the impact of pseudodeficiency alleles on MPS I screening results.
- To inform future NBS strategies for MPS disorders.
Main Methods:
- Analysis of data from two pilot MPS I newborn screening studies in Italy (Tuscany-Umbria and North East Italy).
- Inclusion of alpha-L-iduronidase (IDUA) gene molecular analysis for pseudodeficiency alleles.
- Monitoring of infants with abnormal screening results and variants of unknown significance (VUS).
Main Results:
- In the Tuscany-Umbria pilot, seven out of eight positive infants had pseudodeficiency alleles (p.Ala79Thr, p.His82Gln), with a high prevalence in individuals of African origin.
- The North East Italy experience identified one affected newborn out of 66,491 screened, with a high incidence of pseudodeficiency (1:6044), also noted in patients of African origin.
- One infant showed transient elevation of urine glycosaminoglycans (GAGs) and is under follow-up.
Conclusions:
- The high prevalence of pseudodeficiency alleles, especially in specific ethnic groups, presents a significant challenge for accurate MPS I newborn screening.
- Long-term follow-up is crucial for infants with abnormal NBS results or VUS to determine true risks and benefits.
- The development of combined MPS screening assays and the availability of early treatments for other MPS types may facilitate future NBS pilot studies.
Abstract:
Newborn screening (NBS) methods and therapeutic options have become increasingly available for mucopolysaccharidoses (MPS), and there is a clear evidence that early intervention significantly improves the outcome. It is recommended that mucopolysaccharidosis type I (MPS I) is included in the US newborn screening panel, and this is currently underway in some NBS programs in the world. The key factors in recommending MPS I for inclusion in NBS are the strongly improved efficacy of early-onset therapy and the improved performance of screening tests. Two studies on MPS I screening have been conducted in Italy. In the Tuscany-Umbria pilot NBS, eight infants were confirmed positive, and alpha-L-iduronidase (IDUA) gene molecular analysis showed that seven had either homozygosity or compound heterozygosity for pseudodeficiency alleles. p.Ala79Thr and p.His82Gln changes were demonstrated in four and three infants, respectively, six of which were of African origin. Only one infant had transitory elevation of urine glycosaminoglycans (GAGs) (by quantitative analysis) and she is in follow-up at the time of writing. In the North East Italy experience, there was one affected newborn for 66,491 screened. In this patient treatment started at 1 month of age. In the North East Italy experience the incidence of pseudodeficiency was very high (1:6044), with a high incidence of pseudodeficiency from patients of African origin.A significant problem that is encountered in the follow-up of infants with abnormal NBS and variants of unknown significance (VUS) on molecular analysis results relates to those who cannot be positively identified as either affected or unaffected. Long-term follow-up of these infants, and of those detected with late-onset disorders, will be essential to document the true risks and benefits of NBS. The availability of treatments in MPS II, IVA, VI, and VII with a better clinical outcome when started early in life, and the availability of a combined multiple assay for MPS, may be a prerequisite for new pilot NBS studies in the near future.
Related Concept Videos
Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
Imprinting
Bacterial Transformation
Griffith made an unexpected discovery when he killed the pathogenic strain and mixed its remains with the live, non-pathogenic strain. Not only did the mixture kill host mice, but it also contained living pathogenic bacteria that...
The de Broglie Wavelength
The Energies of Atomic Orbitals

